Roy Jefferis,
Professor Emeritus,
University Of Birmingham
After attaining BSc and PhD in Chemistry I moved to the Medical School (Birmingham) and began research into the structure and function of antibody molecules, in health and disease. Our studies revealed the profound influence that glycosylation of the IgG class of antibody can have on the activation of effector mechanisms, in vitro and in vivo. Extension to the engineering and design of recombinant antibody therapeutics resulted in consultancies with the biopharmaceutical industry. A current focus is the potential for immunogenicity when there is a allotype mismatch between an IgG therapeutic and a patient’s IgG haplotype. In consideration of published research I have been elected Member of the Royal College of Physicians (MRCP) and Fellow of the Royal College of Pathologists (FRCPath).
|
|
Glycosylation of IgG Antibodies: a Critical Quality Attribute (CQA)Wednesday, 20 July 2011 at 16:30 Add to Calendar ▼2011-07-21 10:00:002011-07-21 11:00:00Europe/LondonBiosimilars, Bio-betters, Comparability and Adverse ReactionsSELECTBIOenquiries@selectbiosciences.comThe biologic activities of natural IgG antibodies are determined by the glycoform profile; orchestrated by the immune system. Production cell lines deliver a fixed glycoform profile; therefore, resort is made to cell and protein engineering.
|